Diplomat Pharmacy Faces Shareholder Suit Over Value Drop

By Cara Mannion · November 14, 2016, 6:22 PM EST

Specialty drugmaker Diplomat Pharmacy Inc. overestimated its hepatitis C drug's financial outlook and failed to properly calculate $8 million in Medicare fees, causing share values to plummet by 42 percent once...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Zimmerman v. Diplomat Pharmacy, Inc. et al

Case Number

2:16-cv-14005

Court

Michigan Eastern

Nature of Suit

Securities/Commodities

Date Filed

November 10, 2016